scholarly article | Q13442814 |
P356 | DOI | 10.4088/JCP.V67N0910 |
P698 | PubMed publication ID | 17017826 |
P2093 | author name string | Wen Xu | |
Glenn A Phillips | |||
Dieter Naber | |||
Suraja M Roychowdhury | |||
David L Van Brunt | |||
P433 | issue | 9 | |
P921 | main subject | quality of life | Q13100823 |
P304 | page(s) | 1397-1403 | |
P577 | publication date | 2006-09-01 | |
P1433 | published in | The Journal of Clinical Psychiatry | Q7743563 |
P1476 | title | The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone | |
P478 | volume | 67 |
Q38051283 | An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine |
Q41510821 | Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
Q40664835 | Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS). |
Q37214661 | Do effectiveness ("real world") studies on antipsychotics tell us the real truth? |
Q37917728 | Effectiveness studies: advantages and disadvantages. |
Q35232135 | How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review |
Q36920148 | Measuring health-related quality of life in drug clinical trials: is it given due importance? |
Q94235795 | Olanzapine dose for people with schizophrenia |
Q24236545 | Olanzapine versus other atypical antipsychotics for schizophrenia |
Q47374764 | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. |
Q33291585 | Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings |
Q38113746 | The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia |
Q24240260 | Ziprasidone versus other atypical antipsychotics for schizophrenia |
Search more.